RKVTF (Rakovina Therapeutics) Common Stock : $10.96 Mil (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Rakovina Therapeutics Common Stock?

Rakovina Therapeutics's quarterly common stock increased from Mar. 2024 ($10.05 Mil) to Jun. 2024 ($10.57 Mil) and increased from Jun. 2024 ($10.57 Mil) to Sep. 2024 ($10.96 Mil).

Rakovina Therapeutics's annual common stock declined from Dec. 2021 ($10.61 Mil) to Dec. 2022 ($10.00 Mil) but then increased from Dec. 2022 ($10.00 Mil) to Dec. 2023 ($10.14 Mil).

Rakovina Therapeutics Common Stock Historical Data

The historical data trend for Rakovina Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rakovina Therapeutics Common Stock Chart

Rakovina Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Common Stock

10.61

10.00

10.14

Rakovina Therapeutics Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Common Stock	Get a 7-Day Free Trial										10.04	10.14	10.05	10.57	10.96

Rakovina Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Rakovina Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rakovina Therapeutics Inc (OTCPK:RKVTF) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

7JO:Germany RKV:Canada

Address

595 Burrard Street, P.O. Box 49314, Suite 2600, Three Bentall Centre, Vancouver, BC, CAN, V6B 0A5

Website

https://www.rakovinatherapeutics.com

Rakovina Therapeutics Inc is engaged in drug discovery research, preclinical and clinical development, and regulatory affairs necessary to advance breakthrough innovations to become potential life-changing treatments in the oncology field. Its oncology pipeline has the potential to deliver biomarker-driven treatments for patients across multiple tumor types. Some of its products in the pipeline include kt-2000 AI, kt-3000 series. Rakovina gained exclusive use of the Deep Docking AI Platform, enabling it to significantly speed up identifying potential drugs for DNA damage response.